Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies

被引:3
作者
Bramanti, Stefania [1 ]
De Philippis, Chiara [1 ]
Bartoli, Antonella [2 ]
Giordano, Laura [3 ]
Mariotti, Jacopo [1 ]
Sarina, Barbara [1 ]
Mannina, Daniele [1 ]
Valli, Viviana [1 ]
De Gregori, Simona [2 ]
Roperti, Martina [1 ]
Pieri, Gabriella [1 ]
Castagna, Luca [1 ]
机构
[1] IRCCS Humanitas Res Hosp Humanitas Canc Ctr, Via Manzoni 56, I-20089 Milan, Italy
[2] Fdn IRCCS Policlin San Matteo, Clin & Expt Pharmacokinet Unit, Pavia, Italy
[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy
来源
TRANSPLANTATION AND CELLULAR THERAPY | 2021年 / 27卷 / 11期
关键词
PK-guided busulfan; Allogeneic stem cell transplantation; Reduced-toxicity conditioning regimen; BONE-MARROW-TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; 1ST COMPLETE REMISSION; INTRAVENOUS BUSULFAN; RESPONSE CRITERIA; CLINICAL-TRIALS; OLDER PATIENTS; OPEN-LABEL; PHASE-II; FLUDARABINE;
D O I
10.1016/j.jtct.2021.08.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Busulfan (Bu) is an alkylating agent routinely used for conditioning regimens before allogeneic stem cell transplantation (allo-SCT). Bu shows wide pharmacokinetic (PK) variability among patients. Patients can have a higher systemic exposure (expressed as area under the curve [AUC]) with an increased risk of toxicity or a lower AUC with a higher probability of graft rejection and/or disease relapse. After i.v. administration, an optimal Bu therapeutic window (AUC target of 16,000 to 24,000 mu M.minute) has been identified. The use of PK-guided Bu dosing leads to improved overall survival (OS) and progression-free survival (PFS) compared with fixed-dose administration in a variety of hematologic diseases. The aim of this study was to evaluate the outcomes and feasibility of a reduced-toxicity conditioning (RTC) regimen comprising thiotepa, Bu, and fludarabine (TBF) with therapeutic drug monitoring of Bu in patients with hematologic disorders. We report on 41 adult patients with myeloid or lymphoid malignancies who underwent an allo-SCT with a PK-guided Bu-based RTC regimen between January 2019 and October 2020. Patients received a total Bu dose to achieve a target AUC of 16,000 mu M.minute in combination with Flu and thiotepa. The median time to absolute neutrophil count recovery and transfusion-independent platelet count recovery was 23 days (range, 15 to 42 days) and 29 days (range, 14 to 97 days), respectively. The cumulative incidence (CI) of nonrelapse mortality was 7% at 100 days and 13% at 1 year. Grade 3 liver toxicity was observed in 6 patients. One patient developed sinusoidal obstruction syndrome at day +27. Grade 3 mucositis occurred in 18 patients. Looking at grade >= 3 infections, the CI was 29% at 30 days, 34% at 60 days, 44% at 100 days, and 56% at 1 year. The 180-day CI of grade II-IV acute graft-versus-host disease (GVHD) was 15%, and the 1-year CI of overall chronic GVHD was 20%. With a median follow-up of alive patients of 14.4 months (range, 3.2 to 24 months), the CI of relapse at 1 year was 6%. The 1-year PFS was 81%, and 1-year OS was 84%. In conclusion, these data support the efficacy of PK-guided Bu dose in the context of a TBF conditioning regimen and the feasibility of therapeutic dosage monitoring of i.v. Bu for patients with hematologic diseases. (C) 2021 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:912.e1 / 912.e6
页数:6
相关论文
共 51 条
[21]   Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502 [J].
Devine, Steven M. ;
Owzar, Kouros ;
Blum, William ;
Mulkey, Flora ;
Stone, Richard M. ;
Hsu, Jack W. ;
Champlin, Richard E. ;
Chen, Yi-Bin ;
Vij, Ravi ;
Slack, James ;
Soiffer, Robert J. ;
Larson, Richard A. ;
Shea, Thomas C. ;
Hars, Vera ;
Sibley, Alexander B. ;
Giralt, Sergio ;
Carter, Shelly ;
Horowitz, Mary M. ;
Linker, Charles ;
Alyea, Edwin P. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) :4167-+
[22]   Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors [J].
Diaconescu, R ;
Flowers, CR ;
Storer, B ;
Sorror, ML ;
Maris, MB ;
Maloney, DG ;
Sandmaier, BM ;
Storb, R .
BLOOD, 2004, 104 (05) :1550-1558
[23]   Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].
Doehner, Hartmut ;
Estey, Elihu ;
Grimwade, David ;
Amadori, Sergio ;
Appelbaum, Frederick R. ;
Buechner, Thomas ;
Dombret, Herve ;
Ebert, Benjamin L. ;
Fenaux, Pierre ;
Larson, Richard A. ;
Levine, Ross L. ;
Lo-Coco, Francesco ;
Naoe, Tomoki ;
Niederwieser, Dietger ;
Ossenkoppele, Gert J. ;
Sanz, Miguel ;
Sierra, Jorge ;
Tallman, Martin S. ;
Tien, Hwei-Fang ;
Wei, Andrew H. ;
Lowenberg, Bob ;
Bloomfield, Clara D. .
BLOOD, 2017, 129 (04) :424-447
[24]   Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) [J].
Fayard, Amandine ;
Daguenet, Elisabeth ;
Blaise, Didier ;
Chevallier, Patrice ;
Labussiere, Helene ;
Berceanu, Ana ;
Yakoub-Agha, Ibrahim ;
Socie, Gerard ;
Charbonnier, Amandine ;
Suarez, Felipe ;
Huynh, Anne ;
Mercier, Melanie ;
Bulabois, Claude-Eric ;
Lioure, Bruno ;
Chantepie, Sylvain ;
Beguin, Yves ;
Bourhis, Jean-Henri ;
Malfuson, Jean-Valere ;
Clement, Laurence ;
de la Tour, Regis Peffault ;
Cornillon, Jerome .
BONE MARROW TRANSPLANTATION, 2019, 54 (10) :1586-1594
[25]   National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report [J].
Filipovich, AH ;
Weisdorf, D ;
Pavletic, S ;
Socie, G ;
Wingard, JR ;
Lee, SJ ;
Martin, P ;
Chien, J ;
Przepiorka, D ;
Couriel, D ;
Cowen, EW ;
Dinndorf, P ;
Farrell, A ;
Hartzman, R ;
Henslee-Downey, J ;
Jacobsohn, D ;
McDonald, G ;
Mittleman, B ;
Rizzo, JD ;
Robinson, M ;
Schubert, M ;
Schultz, K ;
Shulman, H ;
Turner, M ;
Vogelsang, G ;
Flowers, MED .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) :945-956
[26]   Cellular and clinical pharmacology of fludarabine [J].
Gandhi, V ;
Plunkett, W .
CLINICAL PHARMACOKINETICS, 2002, 41 (02) :93-103
[27]  
Hassan M, 1998, CLINICIAN'S GUIDE TO CHEMOTHERAPY PHARMACOKINETICS AND PHARMACODYNAMICS, P189
[28]   MEASUREMENT OF BUSULFAN IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
HENNER, WD ;
FURLONG, EA ;
FLAHERTY, MD ;
SHEA, TC ;
PETERS, WP .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 416 (02) :426-432
[29]   Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation [J].
Iacobelli, Simona .
BONE MARROW TRANSPLANTATION, 2013, 48 :S1-S37
[30]  
Kalbfleisch JD., 2011, STAT ANAL FAILURE TI